BioNxt Solutions Inc. has moved its Semaglutide oral dissolvable film program into the active pharmaceutical development phase, collaborating with German partner Gen-Plus GmbH. This advancement targets the growing GLP-1 market, which includes treatments for obesity, metabolic disorders, and type 2 diabetes, aiming to offer a convenient, needle-free sublingual delivery method. The initial development phase will last six to nine months, focusing on formulation and proof-of-concept studies, with potential for future scale-up and intellectual property development. This step marks BioNxt's expansion from a single-product focus to a broader drug delivery platform, emphasizing patient-friendly, portable therapies.
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
Defence Therapeutics has enhanced its internal capabilities in purification, analytical characterization, conjugation development, and quality control to advance its ACCUM-enabled Antibody Drug Conjugates (ADC) pipeline. The company acquired new equi...
U.S. spot Bitcoin ETFs experienced $648.64 million in net outflows on May 18, following $290.42 million outflows on May 15, indicating a short-term defensive shift among institutional investors. BlackRock's IBIT fund led the withdrawals with $448.36 ...
Kornit Digital reported first quarter results that exceeded analyst expectations and provided a Q2 revenue forecast above estimates, signaling strong sales momentum. However, gross margins fell to a two-year low due to tariffs, currency challenges, a...
American Pacific Mining has begun a field reconnaissance and surface sampling program at its Red Hill Gold Project in Nevada to enhance geological understanding and gather geochemical data. Early findings include a significant jasperoid outcrop with ...
